INTRODUCTION
============

It is now well accepted that the effects of the various components of the renin-angiotensin system (RAS) range in various aspects of peripheral and brain functions well beyond those of regulating blood pressure and hydro-mineral balance. In particular, the existence of a complete RAS in the brain is fully acknowledged. Its activation leads to angiotensin II (Ang II) production, which is usually viewed as the end-product of this system ([@B27]). Ang II binds two receptors from the G protein-coupled receptor family (GPCR), namely the angiotensin type 1 (AT~1~) and angiotensin type 2 (AT~2~) receptor. Although physiological functions of the AT~1~ receptor are relatively well-established, ranging from vasoconstriction and aldosterone release to cell growth, the effects associated with the AT~2~ receptor are surrounded by controversy. Both AT~1~ and AT~2~ receptors are expressed in various brain areas involved in the regulation of fluid and electrolyte balance and in the regulation of arterial pressure, as well as in structures involved in cognition, behavior, and locomotion ([@B123]; [@B71]; [@B70]; [@B163], [@B164]; [@B109]).

One of the biggest challenges in studying the AT~2~ receptor is to apply what has been observed using cell lines to *in vivo* models. Indeed, studies using cell lines expressing the AT~2~ receptor either endogenously or by transfection, have provided paramount information regarding its intracellular mechanisms of action, although associating these mechanisms with biological functions has proven to be much more difficult. Indeed, most of the relevant information regarding AT~2~ receptor functions in the brain has emerged from indirect observations, either by use of AT~1~ receptor blockers (ARB) or *via* transgenic "knock-down" animals for AT~2~ receptor expression. The present review summarizes recent advances in AT~2~ receptor signaling pathways, and discusses how they could be related to the neuroprotective functions of the receptor.

BRAIN EXPRESSION AND ROLE OF THE AT~2~ RECEPTOR
===============================================

As summarized in several reviews ([@B27]; [@B125]; [@B42]; [@B163]; [@B109]), the AT~2~ receptor is widely expressed during fetal life, which decreases rapidly after birth ([@B54]; [@B15]; [@B135]; [@B118]), although a recent study has reported opposite results ([@B168]). This study is indeed in sharp contrast with previous reports using more specific methods, like autoradiography or *in situ* hybridization. In the adult, AT~2~ receptor expression is limited to a few tissues and cell types, such as vascular endothelial cells, adrenal gland, kidney, heart, myometrial cells, and ovaries (review in [@B125]; [@B42], [@B43]; [@B155]). In the adult central nervous system (CNS), the AT~2~ receptor is observed in certain specific brain areas involved in the control and learning of motor activity, control of autonomous functions, sensory areas, and selected limbic system structures ([@B94], [@B95]). In particular, it is the major Ang II receptor in the medulla oblongata (control of autonomous functions), septum and amygdala (associated with anxiety-like behavior), thalamus (sensory perception), superior colliculus (control of eye movements in response to visual information) as well as subthalamic nucleus and cerebellum (areas associated with learning of motor functions). On the other hand, certain areas involved in cardiovascular functions, learning, behavior, and stress reactions (cingulate cortex, molecular layer of the cerebellar cortex, superior colliculus, and paraventricular nuclei) contain both AT~1~ and AT~2~ receptors ([@B107]; [@B152]; [@B94], [@B95]). More recently, expression of the AT~2~ receptor was also detected in the substantia nigra pars compacta, an area involved in dopaminergic signals and associated with Parkinson's disease ([@B57]), and in the hippocampus ([@B6]; [@B3]). At the cellular level, the AT~2~ receptor is expressed in neurons, but not in astrocytes ([@B13]; [@B94]; [@B48]). Evidence also suggests that the AT~2~ receptor is expressed in the vasculature wall, where it acts on cerebral blood flow (review in [@B70]; [@B69]). It should also be noted that existence of a non-AT~1~/non-AT~2~ receptor in the CNS has been suggested, which displays high affinity for Ang I, II, and III ([@B87]).

ROLE OF THE AT~2~ RECEPTOR IN NEURONAL EXCITABILITY
---------------------------------------------------

One of the first roles of the AT~2~ receptor to be identified was the modulation of neuronal excitability, which plays a crucial role not only in neuronal differentiation, but also in neuronal functions (review in [@B48]; [@B44]). In particular, in cells of neuronal origin, activation of the AT~2~ receptor decreases activity of T-type calcium channels ([@B17], [@B18]). On the other hand, in rat brain neuronal culture, [@B86] showed that the AT~2~ receptor stimulates a delayed rectifier K^+^ current (I~K~) and a transient K^+^ current (I~A~), an effect dependent on the G-protein Gi and the serine/threonine phosphatase PP2A. Consistent with these observations, a recent study showed that AT~2~ receptor induces a hyperpolarization and a decrease in firing rate in rostral ventrolateral medulla (RVLM) neurons suggesting that central activation of the AT~2~ receptor in this region decreases excitability ([@B102]). More recently, another study using C21/M024 demonstrated that selective stimulation of AT~2~ receptor in the neuronal cell line (called CATH.a neurons) increases the potassium current activity (*I*~Kv~)~(Kv)~ in a nitric oxide (NO)-dependant pathway ([@B44]). Moreover, intracerebroventricular infusion of C21/M024 was associated with a decrease in norepinephrine excretion and in blood pressure. Indeed, the modulation of the receptor on neuronal excitability in this region could be one of the mechanism associated with its effect on blood pressure, since RVLM is often considered as the main regulator of vascular tone (review in [@B34]). An inhibitory effect of the AT~2~ receptor on neuronal excitability has also been observed in the locus coeruleus from brain slice preparations ([@B166]) and in the superior colliculus ([@B106]). Finally, using the selective agonist C21/M024, [@B83] recently demonstrated that direct stimulation of cerebral AT~2~ receptor increases postsynaptic potential, thus corroborating previous *in vitro* observations. Interestingly, AT~2~ receptor-induced neuronal activation of delayed rectifier potassium channels has also been demonstrated to have a neuroprotective effect ([@B55]). In fact, these AT~2~ receptor effects on ionic channel activity suggest that it may be implicated in synaptic plasticity, an important process involved in learning and memory.

ROLE OF THE AT~2~ RECEPTOR IN NEURONAL DIFFERENTIATION
------------------------------------------------------

One of the best recognized effects of AT~2~ receptor stimulation in neuronal cells is the induction of neurite outgrowth (review in [@B42]). In the early 1990s, our group observed that stimulation of the AT~2~ receptor with its selective agonist CGP42112A induces neurite outgrowth in the neuronal NG108-15 cell line ([@B91]), results that were further confirmed using the recently developed non-peptide selective AT~2~ receptor agonist C21/M024 ([@B158]). This effect was associated with an increase in mature neural cell markers, such as βIII-tubulin, and microtubule-associated proteins (MAPs) such as MAP2c ([@B91]), both known to stabilize tubulin in a polymerized state, thus participating actively in differentiation ([@B133]). Similar results have also been reported in the pheochromocytoma-derived cell line PC12W, where Ang II was found to promoted neuronal differentiation characterized by an increase in neurite elongation ([@B105]) and enhanced levels of polymerized βIII-tubulin and MAP2 associated with microtubules ([@B148]). However, neurite outgrowth in PC12W cells has also been associated with a reduced expression of MAP1B ([@B148]) and neurofilament M ([@B39]), two proteins specifically associated with axon elongation ([@B53]). These results were further confirmed in primary neuronal cultures, including retinal explants ([@B99]), microexplant cultures of the cerebellum ([@B23]), in neurospheres from mouse fetal brain ([@B110]) as well as primary cultures of newborn brain cortex neurons ([@B97]) and hippocampal neurons ([@B83]). Some studies also showed that this neurite elongation was associated with an increase in the repair of damaged DNA by induction of methyl methanesulfonate sensitive-2 (MMS2), a neural-differentiating factor ([@B110]; [@B83]). Altogether, these results suggest that activation of the AT~2~ receptor is associated with important rearrangements of the cytoskeleton necessary for induction of neurite elongation.

ROLE OF THE AT~2~ RECEPTOR IN NEURONAL MIGRATION
------------------------------------------------

In cerebellar microexplants, where both neuronal and glial cells are present, AT~2~ receptor activation induces not only neurite outgrowth, but cell migration as well ([@B23]). Indeed, application of Ang II in this model induced cell migration of neurons from the center toward the periphery of the microexplant ([@B23]). These effects were more pronounced in cells treated with Ang II and DUP 753 (known as the ARB losartan) or in cells treated with 10 nM of CGP42112A an AT~2~ receptor agonist, and conversely blocked with the AT~2~ receptor antagonist PD123,319. Similar cell migration has also been observed during AT~2~ receptor-induced regeneration of post-natal retinal microexplants ([@B99]). During migration and neurite outgrowth, cells are characterized by a myriad of advancing, retracting, turning, and branching behavioral patterns. Such dynamics and plasticity are driven by the reorganization of actin and the microtubular cytoskeleton. In particular, during the process of migration, actin filaments play a major role and are putatively considered as the primary target of guidance cues, due to their localization at the cell periphery, and in filopodium in the growth cone, where they are considered to be the driving force for the forward extension of the cell membrane ([@B41]; [@B85]). Our results on NG108-15 cells have shown that the underlying mechanism involves an Ang II-induced decrease in the amount of F-actin in filopodium and an increase in the pool of unpolymerized actin, through a pertussis toxin (PTX)-sensitive increase in ADF/cofilin activity. These latter effects were found to be AT~2~ receptor-dependent, since the increase in the rate of migration was abolished by the selective antagonist PD123,319, but not by the selective AT~1~ receptor antagonist losartan. Interestingly, some co-localization of F-actin with microtubules was also observed in control conditions, but which disappeared during Ang II-induced migration ([@B88]). Among the candidate molecules that possibly cross-link actin filaments and microtubules are MAP2c and MAP1B ([@B32]; [@B31]), proteins previously shown by our group to be affected during the process of AT~2~ receptor-stimulated neurite outgrowth, both in NG108-15 cells and in cerebellar granule cells ([@B91]; [@B23]).

MAIN SIGNALING PATHWAYS OF THE AT~2~ RECEPTOR
=============================================

Although the AT~2~ receptor displays most of the classical features of a GPCR, it is usually considered as an atypical member of this family, since it fails to induce all of the classical signaling pathways such as cAMP, production of inositol triphosphate (IP3) or intracellular calcium release. Signaling pathways associated with the AT~2~ receptor mainly involve a balance between phosphatase and kinase activities and according to whether the cell is undifferentiated or differentiated and whether it expresses angiotensin AT~1~ receptors or not. Thus, there is still much controversy surrounding this receptor, and its effects, either protective or deleterious, remain a subject of debate ([@B161]; [@B145], [@B146]; [@B125]; [@B69]; [@B155]). In our endeavor to elucidate the mechanisms associated with AT~2~ receptor-induced neurite outgrowth, we and others have investigated signaling pathways activated by this receptor, including G-protein coupling, regulation of kinase activity, interaction with growth factor receptors, and production of NO. Moreover, recent observations have also delineated new partners for the AT~2~ receptor which play key functions in its regulation (**Figure [1](#F1){ref-type="fig"}**).

![**Main signaling pathways associated with AT~2~ receptor activation leading to neuroprotective effects (see text for details).** Adapted from [@B42].](fendo-03-00164-g001){#F1}

G-PROTEIN COUPLING
------------------

While coupling of G-protein to AT~1~ receptors is well described ([@B27]; [@B76]), such coupling is not the rule for the AT~2~ receptor. Former studies have described a coupling to subunit Gα~i2~ and Gα~i3~ in rat fetus ([@B170]). In some models (rat hippocampal neurons and other selected cell types), blocking Gα~i~ with PTX or antibodies directed against Gα~i~ inhibited the AT~2~ receptor effects on actin depolymerization, activation of endothelial NO synthase (NOS), stimulation of neuronal K^+^ current and on anti-proliferative activity ([@B86]; [@B122]; [@B98]; [@B121]; [@B88]), indicating that coupling of the AT~2~ receptor to Gα~i~ is at least implicated in these pathways. However, aside from a few exceptions ([@B86]), PTX failed to inhibit either p42/p44^mapk^ activation in the neuronal cell line NG108-15 ([@B46]) or phosphatase activity in several models (for review see [@B117]; [@B48]).

REGULATION OF KINASE ACTIVITY
-----------------------------

### AT~2~ Receptor-induced phosphatase activation

Phosphatase activation has been one of the first signals associated with AT~2~ receptor activation. After the earlier studies in PC12W cells ([@B14]; [@B16]), results have been confirmed in other cell lines, including N1E-115 cells ([@B114]), NG108-15 cells ([@B18]), and R3T3 fibroblasts ([@B153],[@B154]). This phosphatase activation by the AT~2~ receptor is essential for its anti-proliferative and pro-apoptotic effects (for reviews, see [@B117]; [@B145]; [@B125]; [@B155]). Currently, three main phosphatases have been implicated in AT~2~ receptor signaling, namely SH2-domain-containing phosphatase 1 (SHP-1), mitogen-activated protein kinase phosphatase 1 (MKP-1), and the serine--threonine phosphatase PP2A.

SHP-1 is a cytosolic phosphatase rapidly activated by the AT~2~ receptor following Ang II binding. Activation of SHP-1 is associated with AT~2~-induced growth inhibition in various cells, including neuronal cells ([@B10]; [@B35]; [@B36]; [@B97]), vascular smooth muscle cells ([@B25]; [@B101]), CHO, and COS-7 cells transfected with the AT~2~ receptor ([@B35]; [@B36]). Activation of SHP-1 is associated with inhibitory effects of the AT~2~ receptor on the AT~1~ receptor, including transactivation of the epidermal growth factor (EGF) receptor and activation of c-Jun N-terminal kinase (JNK) ([@B101]; [@B141]), but also on insulin-induced activation of the phosphatidylinositol 3-kinase (PI3K), its association with the insulin receptor substrate IRS-2 and phosphorylation of Akt ([@B25]). This inhibition of insulin signaling by AT~2~ receptor-induced SHP-1 activation has also been associated with an increase in PC12W cell apoptosis ([@B26]). More recently, [@B97] have shown that induction of neurite outgrowth in fetal rat neurons by AT~2~ receptor involves the association of SHP-1 with the newly identified AT~2~-receptor interacting protein (ATIP; see section AT~2~ Receptor Interacting Proteins) and an increase in MMS2 protein ([@B97]). Finally, although the mechanisms associated with AT~2~ receptor-induced activation of SHP-1 have yet to be fully elucidated, implication of G-protein coupling ([@B10]; [@B36]) as well as activation of Src kinase ([@B5]) have been reported; other studies have also implicated a constitutive association between AT~2~ receptor and SHP-1 in overexpressing models ([@B36]; [@B108]). Another phosphatase associated with AT~2~ receptor activation is MKP-1, which is a key regulator of p42/p44^mapk^ activity. AT~2~ receptor-activated MKP-1 has been observed in various cell types, including PC12W cells ([@B167]), fibroblasts ([@B68]; [@B20]), and cardiac myocytes ([@B37]; [@B66]). Activation of MKP-1 by AT~2~ leads to a decrease in p42/p44^mapk^ activity, and is associated to growth inhibition induced by the AT~2~ receptor. Moreover, [@B68] demonstrated that AT~2~ receptor-induced MKP-1 activation is implicated in apoptotic effects of the AT~2~ receptor, leading to Bcl-2 dephosphorylation and an increase in Bax, resulting in cell death. Finally, the serine--threonine phosphatase PP2A is also activated by the AT~2~ receptor following Ang II binding and may be associated with AT~2~ receptor regulation of p42/p44^mapk^. Indeed, in primary neuronal cultures, AT~2~ receptor-induced activation of PP2A is associated with inhibition of AT~1~ receptor-induced p42/p44^mapk^ phosphorylation ([@B72], [@B73],[@B74]) and is implicated in AT~2~-induced modulation of potassium currents ([@B72], [@B73]; [@B19]). More recently, we have also shown an implication of PP2A activation in actin depolymerization and an increase in neuronal migration ([@B88]; **Figure [1](#F1){ref-type="fig"}**).

### Mitogen-activated protein kinase p42/p44

Among all signaling pathways associated with AT~2~ receptor activation, regulation of p42/p44^mapk^ is probably the one where variability is the most important. The effect of AT~2~ receptor stimulation on activation or inhibition of p42/p44^mapk^ activity is dependent on the models studied, on whether they express AT~1~ receptors or not and whether cells are under physiological or pathological conditions. Thus, AT~2~ receptor effects on p42/p44^mapk^ remain controversial. Many studies have shown that the AT~2~ receptor leads to dephosphorylation of p42/p44^mapk^ *via* one the phosphatases associated with AT~2~ receptor signaling (see above). This decrease in p42/p44^mapk^ activity is associated with inhibition of growth and pro-apoptotic effects of the AT~2~ receptor (review in [@B116]; [@B125]). In addition to activation of phosphatase, AT~2~ receptor-induced inhibition of p42/p44^mapk^ can be mediated by inhibition of growth factor receptors. Indeed, in vascular smooth muscle cells overexpressing the AT~2~ receptor, stimulation with Ang II decreases EGF receptor phosphorylation and inhibits p42/p44^mapk^ activation ([@B141]). Similar observations have also been reported in CHO cells overexpressing the AT~2~ receptor ([@B35]). Worthy of note is the fact that inhibition of p42/p44^mapk^ induced by the AT~2~ receptor is observed only in certain conditions, such as in cells overexpressing the AT~2~ receptor or already exhibiting pathological conditions such as serum-starving ([@B10]; [@B68]; [@B35]; [@B25]; [@B141]).

By contrast, in neuronal cells such as NG108-15 and PC12W cells, the AT~2~ receptor leads to sustained activation of p42/p44^mapk^. In these cells, activation of p42/p44^mapk^ is essential to AT~2~ receptor-induced neurite elongation ([@B47]; [@B147]). In NG108-15 cells, we observed that this increase in p42/p44^mapk^ activity was associated with the Rap1/B-Raf pathway. However, this Rap1 activation appears to be dependent of nerve growth factor receptor TrkA activation (see latter; [@B124]) rather than through cAMP and protein kinase A (PKA), as usually observed with other GPCR (**Figure [1](#F1){ref-type="fig"}**). This activation of p42/p44^mapk^ by the AT~2~ receptor has also been observed in non-neuronal COS-7 and NIH3T3 cells overexpressing the AT~2~ receptor ([@B61]; [@B30]).

### Src family kinase

There are few studies showing an implication of Src family members in AT~2~ receptor signaling. However, Src family kinases (SFKs) are key regulators in cell growth and differentiation and are implicated in most growth factor signaling pathways. In the CNS, five members of SFK are expressed, namely Src, Fyn, Lyn, Lck, and Yes, where they act as modulators of neurotransmitter receptors as well as in the regulation of excitatory transmission (review in [@B84]; [@B149]; [@B119]). Recently, we have shown that stimulation of the AT~2~ receptor in NG108-15 cells leads to rapid but transient activation of SFK and that expression of inactive Fyn abolished AT~2~ receptor-induced neurite outgrowth in these cells ([@B59]). However, inhibition of Fyn had no effect on other signaling pathways induced by the AT~2~ receptor, including p42/p44^mapk^ and Rap1 activation, suggesting that it may be involved either downstream of these proteins, or in a parallel pathway. Of note, among the five SFKs expressed in the brain, only a deficiency in Fyn-induced neurological deficits, including impairment in spatial learning and in hippocampal development ([@B58]; [@B89]). Interestingly, similar physiological perturbations were also observed in mice lacking the AT~2~ receptor ([@B62]; [@B79]; [@B120]; [@B103]). Therefore, regulation of Fyn activity could be considered as a new player implicated in the protective effect of this receptor in cognitive disorders. Indeed, Fyn has been shown to be involved in tau phosphorylation, thus regulating its affinity for tubulin and stability of microtubules, two parameters implicated in the development of Alzheimer's disease (AD) and other neurodegenerative diseases ([@B92], [@B93]). Thus, it appears that Fyn is involved in the final steps of induction of elongation, but not in the initial events of AT~2~ receptor activation. This implication of Fyn in AT~2~ receptor signaling is further strengthened by the fact that activation of SFKs, as the AT~2~ receptor, was shown to be important for the induction of long-term potentiation, a key element in learning and memory, in CA1 pyramidal neurons of hippocampal slices ([@B169]).

To the best of our knowledge, only one other group has demonstrated the implication of a Src family member in AT~2~ receptor signaling ([@B5]). In this latter study, it was shown that activation of c-Src was present in an immunocomplex including the tyrosine phosphatase SHP-1 and the AT~2~ receptor following Ang II stimulation in rat fetal membranes. Pre-incubation of membranes with the non-selective inhibitor PP2 inhibited SHP-1 activation and c-Src association. These results indicate that c-Src may represent an important step leading to AT~2~ receptor-induced SHP-1 activation. More recently, the same group demonstrated that this association also occurred in hindbrain membranes from post-natal day 15 rats, and was associated with focal adhesion kinase (p85FAK) ([@B137]). These observations strongly suggest that c-Src may also be implicated in cytoskeleton remodeling associated with neurite elongation and neuronal migration induced by the AT~2~ receptor.

LINKING THE AT~2~ RECEPTOR WITH THE GROWTH FACTOR RECEPTORS
-----------------------------------------------------------

Recently, we demonstrated that activation of Rap1/B-Raf/p42/p44^mapk^ pathway by the AT~2~ receptor was dependent on the nerve growth factor receptor TrkA, although the mechanism involved remains unknown ([@B124]). In addition, we further showed that a SFK member was essential for the initial activation of TrkA by the AT~2~ receptor, since pre-incubation of NG108-15 cells with the non-selective inhibitor PP1 disrupted this effect ([@B59]). However, although Fyn was essential for neurite outgrowth induced by the AT~2~ receptor, it did not appear to be implicated in TrkA activation, since expression of a dominant negative form did not impede AT~2~-induced TrkA activation ([@B59]). In light of recent data obtained by Ciuffo's group regarding the involvement of c-Src and other SFK members with AT~2~ receptors ([@B5]; [@B137]), it would be of interest to see whether the association of the AT~2~ receptor with SHP-1 and c-Src is implicated in this transactivation, and whether TrkA could be involved in FAK activation. Interestingly, transactivation of the TrkA receptor in neurons has also been observed for the pituitary adenylyl cyclase-activating polypeptide receptor (PACAP; [@B127]), which is also associated with neuronal development in the cerebellum ([@B8]).

Curiously, although the expression of inactive Fyn is known to disrupt AT~2~ receptor-induced neurite elongation, non-selective inhibition of SFK in NG108-15 cells with the inhibitor PP1 is sufficient to increase neurite elongation to levels similar to those observed with AT~2~ receptor stimulation ([@B59]), which could be a consequence of a decrease in proliferative signal. Indeed, our group showed that induction of neurite outgrowth was associated with a decrease in cell proliferation through inhibition of PKCα and p21^Ras^ ([@B47]; [@B9]). Moreover, as in the case of SFK, inhibition of the platelet-derived growth factor (PDGF) receptor was sufficient to induce neurite outgrowth and to increase microtubule polymerization more extensively than Ang II alone ([@B124]). These findings are in agreement with a previous report demonstrating that expression of an inactive form of the PDGF receptor in PC12 cells was sufficient to increase neurite elongation ([@B156]). However, whether AT~2~ receptor directly inhibits PDGF receptor or inhibits its signaling pathway is still unknown.

NITRIC OXIDE AND CGMP PRODUCTION -- A ROLE FOR BRADYKININ
---------------------------------------------------------

Nitric oxide has been shown to regulate several types of K^+^ channels, including ATP-dependent K^+^ channels and Ca^2+^-activated K^+^ channels (review in [@B126]). Indeed, in neuronal cell lines, observations with the selective AT~2~ receptor agonist C21/M024 revealed that this production of NO induced by AT~2~ was necessary for AT~2~-induced hyperpolarization of potassium channel function ([@B45]). Production of NO following AT~2~ receptor stimulation has been observed in various cell types, such as neuronal cells ([@B22]; [@B24]; [@B46]; [@B171]; [@B113]), vascular endothelial cells ([@B162]; [@B140]; [@B132]; [@B150]; [@B7]) as well as in smooth muscle cells ([@B28]). It is already well accepted that AT~2~ receptor activation plays an important role in the control of renal function particularly in chronic kidney diseases. The AT~2~ receptor is believed to counterbalance the effects of the AT~1~ receptor at least by influencing vasodilation through NO production and natriuresis ([@B21]; [@B142]; [@B144]). This promoter effect of AT~2~ on natriuresis in pathological conditions (obese Zucker rats) was also recently confirmed using C21/M024 ([@B4]). Activation of NOS by the AT~2~ receptor can occur by direct signaling such as in neuronal cells, or indirectly *via* stimulation of bradykinin production and subsequent activation of its receptor B2. Indeed, heterodimerization between the AT~2~ receptor and bradykinin has also been described in PC12W cells ([@B2]). Moreover, it is already known that bradykinin can modulate AT~2~ receptor-induced NO production ([@B143]; [@B50]; [@B136]). Such involvement of B2 receptors in AT~2~ receptor-induced production of NO is of prime importance in the modulation of cerebral blood flow. Indeed, an AT~2~-induced increase in spatial learning was recently observed to be associated with an increase in cerebral blood flow, an effect reduced by co-administration of the B2 receptor antagonist icatibant. This observation strongly suggests that the beneficial effect of the AT~2~ receptor in cognitive function is partly dependent on bradykinin ([@B83]). In addition, [@B1] demonstrated in conscious bradykinin B2-null and wild-type mice that the AT~2~ receptor can induce production of NO in both null and wild-type models, indicating that the B2 receptor may participate in this process, although is not the only means for the AT~2~ receptor to induce NO production.

AT~2~ RECEPTOR ASSOCIATED PROTEINS
----------------------------------

### ATIP

Recently, using a yeast two-hybrid system, the ATIP was cloned and identified as a protein interacting with the C-terminal tail of the AT~2~ receptor ([@B116]). This protein is expressed as five different transcripts, namely ATIP1, ATIP2, ATIP3a, ATIP3b, and ATIP4 (review in [@B130]; [@B69]). While ATIP3 appears to be the major transcript in tissues, ATIP1 and ATIP4 are mainly expressed in the brain, indicating that they may play biological roles in brain functions. ATIP2, on the other hand, is almost undetectable by real-time PCR ([@B33]). In CHO cells expressing the AT~2~ receptor, ATIP is known to decrease growth factor-induced p42/p44^mapk^ activation and DNA synthesis, therefore decreasing cell proliferation, as well as decrease insulin receptor autophosphorylation, similarly to the AT~2~ receptor. Of particular interest is the fact that, although expression of the AT~2~ receptor was essential in this instance, stimulation by Ang II was not necessary, and that ATIP was able to exert its effect by its sole expression. Implication of ATIP in AT~2~ receptor-induced neurite outgrowth has also been reported. In this context, Ang II stimulation of the AT~2~ receptor induces translocation of ATIP with SHP-1 into the nucleus, resulting in the transactivation of MMS2 ([@B97]). Moreover, ATIP, also known as ATBP50 (AT~2~ receptor binding protein of 50 kDa), has been reported as a membrane-associated Golgi protein implicated in intracellular localization of the AT~2~ receptor and necessary for its membrane expression ([@B165]). ATIP3, which is also expressed in the CNS, has been shown to strongly interact with stabilized microtubules in a model of breast cancer, suggesting an implication on cell division, where it induces a delayed metaphase, thus decreasing tumor progression ([@B129]). The brain-specific isoform ATIP4 is highly expressed in the cerebellum and fetal brain, two sites where the AT~2~ receptor is also highly expressed. Therefore considering (i) the previously described function of the AT~2~ receptor in preservation of cognitive function, (ii) the role of ATIP protein in AT~2~ receptor function, and (iii) the link between ATIP protein and microtubule cytoskeleton, it could be suggested that regulation of ATIP expression and regulation of its association with the AT~2~ receptor could be an important element to consider with regard to the development of neurological disorders, such as AD.

### PLZF

Association between the AT~2~ receptor and the promyelocytic leukemia zinc finger (PLZF) protein has been observed using a yeast two-hybrid system ([@B139]). In CHO cells expressing both PLZF and AT~2~ receptors, Ang II stimulation induces co-localization of PLZF with the AT~2~ receptor, followed by internalization of the complex. This observation is in contrast with other studies observing no internalization of the AT~2~ receptor following Ang II stimulation ([@B75]; [@B63]). Since internalization of the receptor was observed only in cells expressing PLZF, this could represent a new regulatory pathway of AT~2~ receptor function, specific only to selected cell types. However, beside internalization of AT~2~ receptor, a recent study showed that PLZF was implicated in neuroprotection in a stroke model ([@B138]). In this study, the authors showed that PLZF exerts neuroprotective effect in a model of *in vitro* glutamate toxicity. They also showed that overexpression of PLZF in neuronal cells in culture induced a significant increase in AT~2~ receptor expression, suggesting that PLZF could also be implicated in the regulation of AT~2~ receptor expression.

### PPARγ

A new partner for the AT~2~ receptor has recently emerged from the study of [@B172] who observed that neurite outgrowth induced by AT~2~ receptor stimulation in PC12W cells was dependent on the activation of peroxisome proliferator-activated receptor gamma (PPARγ). This observation is in keeping with the implication of PPARγ in NGF-induced neurite outgrowth in the same cell type ([@B38]), clearly suggesting a possible crosstalk between the AT~2~ receptor and NGF pathways. This hypothesis is further reinforced by the observation that inhibition of the NGF receptor TrkA significantly decreases AT~2~ receptor-induced neurite outgrowth ([@B124]). Moreover, [@B81], using atherosclerotic ApoE-KO mice with an AT~2~ receptor deficiency (AT2R/ApoE double knockout mice), observed that the lack of AT~2~ receptor expression decreased the expression of PPARγ in adipocytes cells. These observations strongly suggest a link between the AT~2~ receptor and PPARγ functions. PPARγ is a transcriptional factor regulating the expression of multiple genes, hence promoting the differentiation and development of various tissues, specifically in adipose tissue, brain, placenta, and skin. Interestingly, neuroprotective effects of PPARγ agonist have also been observed (review in [@B49]). However, a major component of the hypothesis regarding the possible implication of PPARγ in AT~2~ receptor function is the PPARγ-like activity associated with certain ARBs, including telmisartan, irbesartan, and candesartan ([@B11]; [@B134]; review in [@B69]). Indeed, there is some evidence suggesting that this PPARγ activation following blockade of the AT~1~ receptor could be part of its anti-inflammatory and anti-oxidative effects, leading to neuroprotection against ischemia and amyloid β (Aβ) accumulation ([@B151]; [@B82]; [@B160]). PPARγ has also been implicated in neural cell differentiation and death, as well as inflammatory and neurodegenerative conditions (review in [@B49]).

LESSONS FROM NEURONAL DIFFERENTIATION: HOW CAN THE AT~2~ RECEPTOR IMPROVE BRAIN FUNCTION?
=========================================================================================

ROLE OF THE AT~2~ RECEPTOR IN NEURONAL REGENERATION
---------------------------------------------------

The capacity for nerve regeneration in lower vertebrates has been mostly lost in higher vertebrates and regeneration within the CNS in mammals is essentially inexistent. However, after injury in the peripheral nervous system, regeneration can be achieved successfully. Observations that AT~2~ receptor stimulation induces neurite elongation associated with modulation of MAP expression strongly suggested that this effect could also be observed following nerve injury. In 1998, two studies demonstrated that the AT~2~ receptor improved nerve recovery in both optic ([@B99]) and sciatic ([@B40]) nerve following nerve crush or in perivascular nerves implicated in vasodilation ([@B67]). This effect was accompanied by an increase in AT~2~ receptor expression, the activation of NFκB and induction of growth-associated protein (GAP-43) leading to a reduction in lesion size. Moreover, [@B128] demonstrated that activation of NFκB by the AT~2~ receptor was an essential step to recovery following sciatic nerve crush. This implication of AT~2~ receptor in neuronal regeneration has even led to the suggestion that Ang II, *via* the AT~2~ receptor, could act as a neurotrophic factor.

AT~2~ RECEPTOR IN COGNITIVE FUNCTION
------------------------------------

There is increasing evidence suggesting that the AT~2~ receptor could be associated with improvement of cognitive function following cerebral ischemia-induced neuronal injury ([@B80]; [@B96]; [@B110]; [@B104]). Indeed, it has been shown that central administration of CGP42112A increases neuronal survival and minimizes experimental post-stroke injury ([@B104]), indicating that activation of brain AT~2~ receptors exhibits a neuroprotective effect. More recently, stimulation of the AT~2~ receptor with the selective agonist C21/M024 was observed to prevent cognitive decline in an AD mouse model with intracerebroventricular injection of Aβ(1-40) ([@B83]). Indeed, some of the signaling pathways described above may be linked to improvement in impaired signaling functions as observed in AD. One of the major hallmarks of AD is Aβ deposition in senile plaques and the presence of neurofibrillary tangles (NFTs). Formation of NFTs is a consequence of protein tau accumulation, due to its hyperphosphorylation, and the dissociation of microtubules. Thus, regulation of tau phosphorylation is of paramount importance with regard to AD progression. On the other hand, several studies have reported that the AT~2~ receptor activates PP2A phosphatase ([@B72], [@B73]; [@B88]), which is markedly deficient in AD ([@B52], [@B51]; [@B159]) and implicated in glycogen synthase kinase-3 (GSK-3) inactivation *via* a sustained increase in p42/p44^mapk^. Since tau is a substrate for PP2A phosphatase, GSK-3 and Fyn, the latter of which is also implicated in the AT~2~ receptor effect on neurite outgrowth ([@B59]), AT~2~ receptor activation could participate in controlling the equilibrium between tau phosphorylation and dephosphorylation ([@B64]; [@B60]; [@B65]). In addition to acting on tau regulation, the AT~2~ receptor may also improve neurite architecture, through effects on MAPs, as observed in neuronal cell lines ([@B91]; [@B105]; [@B23]; [@B97]). The observation that central AT~2~ receptor activation using its selective agonist C21/M024 decreases cognitive loss induced by Aβ intracerebroventricular injection lends further support to this hypothesis ([@B83]). Although the mechanisms underlying these neuroprotective effects of the AT~2~ receptor remain to be fully elucidated, they may include PPARγ and the protein MMS2 ([@B110], [@B111]; for recent reviews see [@B42], [@B43]).

Moreover, as indicated earlier, another important feature of AT~2~ receptor signaling is induction of NO and cGMP production. Recently, [@B83] observed that direct stimulation of central AT~2~ receptors increases NO *via* a bradykinin-dependent pathway, an effect which leads to an increase in cerebral blood flow and enhanced spatial memory. A further study also showed that administration of C21/M024 reduced early renal inflammatory response with production of NO and cGMP ([@B100]). This increase in NO-cGMP production has also been shown to lead to a decrease in nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) superoxide production ([@B157]; [@B161]; [@B29]; [@B145]; [@B78]), thus reducing oxidative stress and potentially associated neuronal apoptosis. This hypothesis is coherent with the observation that the AT~2~ receptor attenuates chemical hypoxia-induced caspase-3 activation in primary cortical neuronal cultures ([@B56]). Finally, inflammation is also a common feature of neurodegenerative diseases. In this regard, a recent study conducted in primary cultures of human and murine dermal fibroblasts, has shown that C21/M024 has anti-inflammatory effects, inhibiting tumor necrosis factor (TNF)-α-induced interleukin-6 levels and NFκB activity. This effect was notably initiated through increased activation of protein phosphatases and increased synthesis of epoxyeicosatrienoic acid ([@B131]).

CONCLUSION
==========

Since its identification in the early 90s, the AT~2~ receptor has been and still is shrouded by controversy, its low expression in the adult and its atypical signaling pathways adding to the challenge of studying this receptor. Thanks to the major advances achieved in the past few years, several studies have confirmed that stimulation of the AT~2~ receptor activates multiple signaling pathways which are linked to beneficial effects on neuronal functions (including excitability, differentiation, and regeneration), inflammation, oxidative stress, and cerebral blood flow (**Figure [1](#F1){ref-type="fig"}**). Several neurodegenerative diseases (including cognitive deficits and dementia) are closely associated with these neuronal and synaptic dysfunctions ([@B77]; [@B173]; [@B90]; [@B12]; [@B112]; [@B115]). Moreover, an increasing number of studies suggest that the protective effects of ARBs on brain damage and cognition may result not only from the inhibition of AT~1~ receptor effects, but also from the beneficial effect due to unopposed activation of the AT~2~ receptor. Thus, if further research confirms the promising early results obtained with the recently developed selective non-peptide AT~2~ receptor agonist C21/M024, the latter may represent a new pharmacological tool in the fight against neurological cognitive disorders. In addition, unraveling the underlying effects of the AT~2~ receptor on neuronal plasticity may lead to the development of even more potent and selective therapies.
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